Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study

Experts discuss first-line treatment strategies for renal cell carcinoma (RCC) in 2025, navigating the evolving therapeutic landscape.

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after immune-oncology (IO)–based therapy.

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

Experts discuss the efficacy profile of tivozanib monotherapy and clinical management strategies in advanced renal cell carcinoma (RCC).

Experts discuss optimizing VEGFR-tyrosine kinase inhibitor (TKI) therapy, focusing on patient selection and management strategies in the clinical setting.

Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Experts discuss patient-reported outcomes from the TiNivo-2 trial, focusing on quality of life and the treatment experience.

Experts discuss optimizing renal cell carcinoma (RCC) treatment by integrating patient-reported outcomes and clinician insights.